


Conflow Cement and Conflow G Bone Cement



- Reduced viscosity – flexibility to fit different needs and applications
- Clinically proven and reliable performance¹⁻⁸
- Conflow G Bone Cement includes gentamicin – broad antibacterial spectrum and proven high release^{9,10*}

Conflow Bone Cement and Conflow G Bone Cement

Zimmer Biomet has decades of experience in bone cement and cementing systems. With the introduction of the Conflow Bone Cement and Conflow G Bone Cement, we complement and expand our bone cement family with a reduced viscosity cement. Conflow Bone Cements can perform as either medium or low viscosity, thereby offering an option for every surgeon's needs.

With a reduced viscosity the cement will flow more easily which makes it ideal for syringe filling used in a lot of anatomical applications. In addition, the Conflow Bone Cements could be an option for larger joints arthroplasty when a low or medium viscosity alternative is preferred.

REDUCED VISCOSITY – A BONE CEMENT WITH EASY FLOW

- Has reduced viscosity and can either perform as a medium or low viscosity bone cement depending on the time and temperature, thereby offering the flexibility to fit different needs and preferences.

CLINICALLY PROVEN WITH RELIABLE LONG-TERM RESULTS¹⁻⁸

- When used in total hip arthroplasty, 2, 5 and 10-year RSA data, collected in the EU on Conflow Bone Cement, show satisfactory results with performance equivalent to the control group bone cement.¹⁻⁵ In addition, data from the Scandinavian registers (Norway and Sweden) demonstrated survival rate in total hip and knee arthroplasty similar to other bone cements.⁶⁻⁸


MECHANICAL PROPERTIES EXCEEDING INTERNATIONAL STANDARDS^{10*,11}

- The mechanical properties of bone cement are tested for compressive strength, bending strength and bending modulus according to ISO 5833.¹¹ Conflow Bone Cement and Conflow G Bone Cement meet the applicable requirements of this standard.^{10*}


HANDLING PROPERTIES

Handling properties are highly dependent on the temperatures of the bone cement and the operating room. Higher temperatures provides a shorter working phase and a faster setting time. It is therefore very important that the cement user becomes familiar with the cement properties, handling and use, and uses the same standardized handling technique every time.


CONFLOW BONE CEMENT NON-PRECHILLED, MANUAL APPLICATION



CONFLOW G BONE CEMENT NON-PRECHILLED, MANUAL APPLICATION



GENTAMICIN COVERAGE¹⁵



ANTIBIOTIC-LOADED BONE CEMENT MAY REDUCE RISK FOR RE-INFECTION¹²

Conflow G Bone Cement includes 1g active gentamicin per 40g unit. The cement is to be used for fixation of joint prostheses to living bone in the second stage of a two-stage revision for total joint arthroplasty after the initial infection has been cleared.


The majority of all bacteria that can be isolated during hip operations are gram-positive, with staphylococci having the greatest share. Among gram-negative bacteria, *E. coli* and pseudomonas are the most common.^{13,14}

The use of antibiotic-impregnated cement has in hip revision shown to reduce the risk of a re-infection.¹²

GENTAMICIN – FOR BROAD COVERAGE

Gentamicin has shown to be the antibiotic of choice for bone cement, as its broad therapeutic spectrum covers gram-positive and gram-negative bacteria. Gentamicin is bactericidal on proliferating and resisting pathogens, and its release from the bone cement is superior to that of other antibiotics.¹⁵

GENTAMICIN RELEASE CONFLOW G BONE CEMENT



Conflow G Bone Cement has shown to provide high local concentrations of gentamicin over several days.^{10*}

Ordering Information

Description	Size	Units per box	Part Number
Conflow Bone Cement	1 x 40g	1	110043025
Conflow G Bone Cement	1 x 40g	1	110043026

References

1. Söderlund, P. *et al.* 10 year results of a new low-monomer cement. *Acta Orthopaedica*. 83(6):604-8, 2012.
2. Pitto, RP *et al.* Cemex Genta bone cement in total hip arthroplasty. Clinical outcome and radiostereoanalysis of 25 hips with 2-year follow-up. South Auckland Clinical School, 2003.
3. Pitto, RP Cemex System Genta bone cement in total hip arthroplasty: clinical outcome and radiostereoanalysis. A 5-year follow-up. South Auckland Clinical School, 2007.
4. Dahl, J., *et al.* Less wear with aluminium-oxide heads than cobalt-chrome heads with ultra-high molecular weight cemented polyethylene cups: a ten-year follow-up with radiostereometry. *International Orthopaedics*. 36(3):485-90, 2012.
5. Nivbrant, B *et al.* Bone cement with reduced proportion of monomer in total hip arthroplasty: pre-clinical evaluation and randomized study of 47 cases with 5 years' follow-up. *Acta Orthopaedica Scandinavica*. 72(6):572-84, 2001.
6. Norwegian Arthroplasty Register (NAR). Survival rate – Hip arthroplasty. Report 2017.
7. Norwegian Arthroplasty Register (NAR). Survival rate – Knee arthroplasty. Report 2017.
8. Swedish Hip Arthroplasty Register (SHAR). Survival rate – Hip arthroplasty. Report 2018.
9. Squire, MW, *et al.* Premixed Antibiotic Bone Cement. An In Vitro Comparison of Antimicrobial Efficacy. *The Journal of Arthroplasty*. 23(6), Suppl. 1, 2008.*
10. Data on file at TECRES S.P.A. Conflow and Conflow G Bone Cement Characterization and AB release.*
11. ISO 5833, Implants for Surgery-Acrylic Resin Cements, 2002.
12. Parvizi, J., *et al.* Efficacy of antibiotic-impregnated cement in total hip replacement. A meta-analysis. *Acta Orthopaedica Scandinavica*. 79 (3): 335-41, 2008.
13. Kayser, F.H. *et al.* Bacteriological aspects of deep wound sepsis after total hip arthroplasty. In Marti, R. K. (Ed.). Progress in cemented total hip surgery and revision. Proceedings of a symposium. Amsterdam. October 16, 1982. Excerpta Medica. 7-17, 1983.
14. Steinbrink, K., *et al.* Behandlung der periprothetischen Infektion der Hüfte durch einzeitige Austauschoperation. (Treatment of periprosthetic infection of the hip by a onestage exchange operation). *Orthopäde*. 24: 335-43, 1995.
15. Kühn, K-D. Bone Cements, Up-to-Date Comparison of Physical and Chemical Properties of Commercial Materials. pp. 254-58. Springer Verlag: Berlin, 2000.

*Laboratory studies not necessarily indicative of clinical performance.

All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet. This material is intended for health care professionals, Zimmer Biomet employees, and the Zimmer Biomet sales force. Distribution to any other recipient is prohibited. For indications, contraindications, warnings, precautions, potential adverse effects and patient counselling information, see the package insert or contact your local representative; visit www.zimmerbiomet.com for additional product information. Not for distribution in France.

©2021 Zimmer Biomet



 **Legal Manufacturer**
TECRES S.P.A.
Via A. Doria, 6
37066 Sommacampagna
(VR) Italy